";} /*B6D1B1EE*/ ?>

test

Contact:

Mag. Johanna Uhlmann
Head of Business Development

Marinomed Biotechnologie GmbH

Tel: +43 (0)1 25077 4460
johanna.uhlmann@marinomed.com

Press Release (November 2012)

Marinomed Granted Chinese Patent for Antiviral Polymer

PDF

 

Vienna, Austria – 19 November 2012 - Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, today announced that it has been granted Chinese Patent No. CN101678040, entitled ‘Antiviral polymer’, by the Chinese patent office. The patent covers the use of a specific polymer for the prevention and treatment of rhinovirus infections.

Dr. Andreas Grassauer, CEO and co-founder of Marinomed, commented:
“The national granting of this patent is an important further step in protecting Marinomed’s intellectual property and know-how around our anti-viral product portfolio based on our mavirex technology platform. Furthermore this patent contributes value in the out-licensing of our products or technology to partner companies in China.”

Marinomed has an anti-viral product portfolio for the prevention and treatment of common cold and influenza. The products include the patent protected polymer Carragelose®; a polymer of the mavirex technology platform. Marinomed’s anti-viral OTC portfolio is already marketed in- and out-side of the EU. The lead product is an anti-viral nasal spray against common cold for adults and children starting from age 1, pregnant and breastfeeding women. 

- ends -

About Marinomed Biotechnologie GmbH
Marinomed Biotechnologie GmbH was founded in 2006 and develops therapies against respiratory diseases based on an innovative anti-viral respiratory technology platform. The usability of this safe and effective technology has been proven by its first marketed product: an anti-viral nasal spray. The huge potential of the technology is reflected by Marinomed’s additional products concentrating on influenza, combination products for asthmatics and other high-risk patients. In addition, the Company develops a novel treatment against type I allergy and autoimmune diseases. Marinomed Biotechnologie GmbH is a spin-off from the Veterinary University Vienna and is located in Vienna, Austria. 

For further information, please visit the website at www.marinomed.com. 

Contact:

Marinomed Biotechnologie GmbH
Johanna Uhlmann
Business Development
Tel: +43 (0)1 25077 4460
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

College Hill Life Sciences
Dr. Robert Mayer
Account Director
T: +44 (0)207 866 786
This e-mail address is being protected from spambots. You need JavaScript enabled to view it